The future for Derma?, page-19

Patients or patience?

I think mxc are at the crossroads. A few things go right and line up (varm Cosmo, strong cannepil sales, Malta development, full gmp, other deals in the wings) and this share is significantly de-risked completely re-rated to 25c+....

conversely if VC falls over the company has approx 12million in bank with a high cash burn and currently minimal income (we’ll know more Monday). They have 6 million euro commitment to Malta which is currently about 9.6 million aud. Cleary if there isn’t significant revenue within 3-6 months (maybe sooner) a CR is on the cards. That will result in more dilution, less trust of managements capabilities and a share price languishing sub 6 cents imo.

I hope the best scenario unfolds for all shareholders and it’s obviously in the directors best interests for income to flow sooner rather than later. I’m sure they are aware of that!

Here’s hoping to REAL revenue in the bank ASAP